Safety and statin therapy: reconsidering the risks and benefits.
Gotto
Antonio M
AM
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D009135:Muscular Diseases / Q000139:chemically induced; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000139:chemically induced; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D008148:Lovastatin; C086276:cerivastatin; D000637:Transaminases; D003402:Creatine Kinase; D017035:Pravastatin